Abstract
Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases. The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decrease in proliferation, angiogenesis, migration, and cell resistance to chemotherapy. Targeting single HDAC isoforms with selective inhibitors will help to reveal the role of individual HDACs in cancer development or uncover further biological consequences of protein acetylation. This review focuses on conventional zinc-containing HDACs. In its first part, the biological role of individual HDACs in various types of cancer is summarized. In the second part, promising HDAC inhibitors showing activity both in enzymatic and cell-based assays are surveyed with an emphasis on the inhibitors selective to the individual HDACs.
Keywords: Epigenetic regulation and cancer, histone deacetylases (HDACs), HDAC inhibitors as anticancer agents, isoform selective HDAC inhibitors, role of HDAC isoforms in cancer.
Current Pharmaceutical Design
Title:Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Volume: 21 Issue: 11
Author(s): Jakub Kollar and Vladimir Frecer
Affiliation:
Keywords: Epigenetic regulation and cancer, histone deacetylases (HDACs), HDAC inhibitors as anticancer agents, isoform selective HDAC inhibitors, role of HDAC isoforms in cancer.
Abstract: Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases. The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decrease in proliferation, angiogenesis, migration, and cell resistance to chemotherapy. Targeting single HDAC isoforms with selective inhibitors will help to reveal the role of individual HDACs in cancer development or uncover further biological consequences of protein acetylation. This review focuses on conventional zinc-containing HDACs. In its first part, the biological role of individual HDACs in various types of cancer is summarized. In the second part, promising HDAC inhibitors showing activity both in enzymatic and cell-based assays are surveyed with an emphasis on the inhibitors selective to the individual HDACs.
Export Options
About this article
Cite this article as:
Kollar Jakub and Frecer Vladimir, Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612820666141110164604
DOI https://dx.doi.org/10.2174/1381612820666141110164604 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Statins and Left Ventricular Function
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Clinical Pharmacology Extracellular Vesicles and Insulin Resistance: A Potential Interaction in Vascular Dysfunction
Current Vascular Pharmacology The Fetal Cardiac Function
Current Cardiology Reviews Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Experimental Antiarrhythmic Targets: CaMKII Inhibition – Ready for Clinical Evaluation?
Current Medicinal Chemistry Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review
Central Nervous System Agents in Medicinal Chemistry Causes and Effects of Cellular Oxidative Stress as a Result of MDMA Abuse
Current Pharmaceutical Biotechnology Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Systemic Approach to Parenteral Nutrition in the ICU
Current Drug Safety Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Preliminary Perspectives on DNA Collection in Anti-Human Trafficking Efforts
Recent Advances in DNA & Gene Sequences (Discontinued) Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy
Current Signal Transduction Therapy Reactive Oxygen-Induced Cardiac Intracellular Pathways During Ischemia and Reperfusion
Current Signal Transduction Therapy Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry